All In MedTech

Device Trial Radar · NCT03206502

Embrace: Seizure Characterization

Characterizing Sleep, Stress, and Seizures in Daily Life: An Internet-based Study With the Empatica Embrace Watch and Smartphone-based Diary-alert System

Last checked: Nov 19, 2026Latest source record: Aug 24, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

100,000

Planned (sponsor's estimate)

Start

May 2016

Primary completion

May 2026

Study completion May 2026

Sponsor

Lead sponsor
Empatica, Inc.Not on our public-company list
Sponsor type
Industry
First posted
Jul 2, 2017

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Diagnostic
FDA-regulated device
Yes
Who can join
All sexes, from 1 year, up to 99 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The study is intended to characterize sleep, stress, and seizures in daily life with the Empatica Embrace watch and smartphone-based diary-alert system. The primary study objective is to collect and validate biometric signals from epilepsy patients using the Empatica Embrace watch and compare them to ictal events captured from human (patient and caregiver) reports.

Conditions

  • Epilepsy

Interventions

  • Embrace + Alert AppDevice

    Participants will wear an Embrace smartwatch to collect data, and will provide survey/diary information on the occurrence of seizures. The device sends data to the Alert app, which issues either true detections or false alarms when it detects a possible convulsive seizure. Participants are asked to either cancel (in real time) or mark (at a later time) all false alarms using the Alert app.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Sensitivity of the GTCS detection of the Embrace + Alert appTime frame: The primary outcome is assessed continuously over the trial period (each new seizure is counted and summed for each person; the average time period is 6 months)

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.